Poster Session 2
AB056. PS02.20: Left sided VATS + subxiphoid for radical thymectomy
Mediastinum
2017;
1:
AB056
(12 September 2017)
Poster Session 2
AB055. PS02.19: Should pulmonary metastasectomy be performed in the thymoma?
Mediastinum
2017;
1:
AB055
(12 September 2017)
Poster Session 2
AB054. PS02.18: Thymic epithelial tumours and additional malignancies: an unresolved enigma
Mediastinum
2017;
1:
AB054
(12 September 2017)
Poster Session 2
AB053. PS02.17: The TYME network of expert centres presents the first Italian consensus conference for thymic epithelial tumours
Mediastinum
2017;
1:
AB053
(12 September 2017)
Poster Session 2
AB052. PS02.16: Minimally invasive treatment by robotic surgery of thymoma B2 stage IVA
Mediastinum
2017;
1:
AB052
(12 September 2017)
Poster Session 2
AB051. PS02.15: Results of extended thymectomy in thymomatous myasthenia gravis
Mediastinum
2017;
1:
AB051
(12 September 2017)
Poster Session 2
AB050. PS02.14: Interference of myasthenia gravis (MG) with long term prognosis of thymoma
Mediastinum
2017;
1:
AB050
(12 September 2017)
Poster Session 2
AB049. PS02.13: Platinum based chemotherapy in locally advanced non-metastatic thymic carcinoma
Mediastinum
2017;
1:
AB049
(12 September 2017)
Poster Session 2
AB048. PS02.12: Pre-operative CT staging is an accurate predictor of post-operative histological staging
Mediastinum
2017;
1:
AB048
(12 September 2017)
Poster Session 2
AB047. PS02.11: Thymic mesenchymal neoplasia: a single institution experience
Mediastinum
2017;
1:
AB047
(12 September 2017)
Poster Session 2
AB046. PS02.10: ROBOTIC thymectomy for early stage thymoma: single center experience
Mediastinum
2017;
1:
AB046
(12 September 2017)
Poster Session 2
AB045. PS02.09: Video-assisted thoracic surgery for thymoma: long-term follow up results and prognostic factors
Mediastinum
2017;
1:
AB045
(12 September 2017)
Poster Session 2
AB044. PS02.08: Surgery for TET in the era of translational research: towards a workflow model incorporating the biobank
Mediastinum
2017;
1:
AB044
(12 September 2017)
Poster Session 2
AB043. PS02.07: Features of thymoma-associated myasthenia gravis: a retrospective analysis on 346 patients
Mediastinum
2017;
1:
AB043
(12 September 2017)
Poster Session 2
AB042. PS02.06: Early outcomes and hospital stay following surgery for thymic masses—robotic versus open surgery
Mediastinum
2017;
1:
AB042
(12 September 2017)
Poster Session 2
AB041. PS02.05: Predictive value of 18FDG-PET/CT on preoperative management of thymic tumours
Mediastinum
2017;
1:
AB041
(12 September 2017)
Poster Session 2
AB040. PS02.04: DOTATATE PET/CT in thymic atypical carcinoid tumor with secondary ACTH-dependent Cushing’s syndrome
Mediastinum
2017;
1:
AB040
(12 September 2017)
Poster Session 2
AB039. PS02.03: The risk of developing extrathymic malignancies in patients with thymoma after surgery
Mediastinum
2017;
1:
AB039
(12 September 2017)
Poster Session 2
AB038. PS02.02: Proposal for refined classification of thymectomy
Mediastinum
2017;
1:
AB038
(12 September 2017)
Poster Session 2
AB037. PS02.01: Is it necessary a superpower to detect thymoma?
Mediastinum
2017;
1:
AB037
(12 September 2017)
Poster Session 1
AB036. PS01.18: Thymoma: a review of the clinical and pathological findings in 66 cases
Mediastinum
2017;
1:
AB036
(12 September 2017)
Poster Session 1
AB035. PS01.17: Primary thymic adenocarcinoma with signet ring cell features to a 39-year-old male: a case report
Mediastinum
2017;
1:
AB035
(12 September 2017)
Poster Session 1
AB034. PS01.16: A case of thymic cyst with papillary proliferation of ciliated epithelium
Mediastinum
2017;
1:
AB034
(12 September 2017)
Poster Session 1
AB033. PS01.15: Relevance of adhesion molecules for killing of thymoma and thymic carcinoma
Mediastinum
2017;
1:
AB033
(12 September 2017)
Poster Session 1
AB032. PS01.14: Epithelial tumours of the thymus: experience with a national database on prognostic factors and treatment
Mediastinum
2017;
1:
AB032
(12 September 2017)
Poster Session 1
AB031. PS01.13: Clinicopathological characteristics and prognostic factors of patients with thymic carcinoma
Mediastinum
2017;
1:
AB031
(12 September 2017)
Poster Session 1
AB030. PS01.12. A phase II study of regorafenib in patients with thymoma and thymic carcinoma previously treated with chemotherapy
Mediastinum
2017;
1:
AB030
(12 September 2017)
Poster Session 1
AB029. PS01.11. Thymomas are the potential candidates for the immune checkpoint inhibitors therapy
Mediastinum
2017;
1:
AB029
(12 September 2017)
Poster Session 1
AB028. PS01.10. Iodine-125 SEED implantation for thymic tumor pleural relapse after failure of chemoradiotherapy
Mediastinum
2017;
1:
AB028
(12 September 2017)
Poster Session 1
AB027. PS01.09. In-progress: phase 1b study of anetumab ravtansine in patients with mesothelin-expressing malignancies
Mediastinum
2017;
1:
AB027
(12 September 2017)
Poster Session 1
AB026. PS01.08. Acetylcholine receptor antibody levels correlate with clinical status in myasthenic thymomas and non-thymomas
Mediastinum
2017;
1:
AB026
(12 September 2017)
Poster Session 1
AB025. PS01.07. Appropriate time to adjuvant radiotherapy for thymoma with myasthenia gravis after extended thymectomy
Mediastinum
2017;
1:
AB025
(12 September 2017)
Poster Session 1
AB024. PS01.06. Exploring the genomic heterogeneity of the combined B2-B3 thymoma and nodal metastasis
Mediastinum
2017;
1:
AB024
(12 September 2017)
Poster Session 1
AB023. PS01.05. Clinical outcomes for stage-III thymic squamous carcinoma
Mediastinum
2017;
1:
AB023
(12 September 2017)
Poster Session 1
AB022. PS01.04. Myasthenia gravis in thymic epithelial tumors incidence and prognosis
Mediastinum
2017;
1:
AB022
(12 September 2017)
Poster Session 1
AB021. PS01.03. Copy number alteration and gene expression analysis of surgically resected thymic epithelial tumors
Mediastinum
2017;
1:
AB021
(12 September 2017)
Poster Session 1
AB020. PS01.02. Identification of potential biomarkers in thymectomy specimen from myasthenia gravis patients in the MGTX-trial
Mediastinum
2017;
1:
AB020
(12 September 2017)
Poster Session 1
AB019. PS01.01. Diagnostic and prognostic implications of fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in thymic epithelial tumors
Mediastinum
2017;
1:
AB019
(12 September 2017)
Surgery
AB018. OS04.04. Is video-assisted thymectomy appropriate for large thymomas? Results of a propensity score matching analysis
Mediastinum
2017;
1:
AB018
(12 September 2017)
Surgery
AB017. OS04.03. Impact of lymph node dissection for thymic malignancies: multi-institutional propensity score matched analysis
Mediastinum
2017;
1:
AB017
(12 September 2017)
Surgery
AB016. OS04.02. Comparision of left and right-sided approach video-assisted thymectomy for centrally located thymic tumors
Mediastinum
2017;
1:
AB016
(12 September 2017)
Surgery
AB015. OS04.01. Robotic thymectomy in thymic epithelial tumors: a propensity score matching study of 112 consecutive cases
Mediastinum
2017;
1:
AB015
(11 September 2017)
Translational Science
AB014. OS03.04. Thymic epithelial tumors phenotype relies on MIR-145-5p epigenetic regulation
Mediastinum
2017;
1:
AB014
(12 September 2017)
Translational Science
AB013. OS03.03. Quantitative proteomic analysis of type B thymoma using data independent acquisition mass spectrometry
Mediastinum
2017;
1:
AB013
(12 September 2017)
Translational Science
AB012. OS03.02. Paraneoplastic syndrome and survival in thymic epithelial tumors the IU experience
Mediastinum
2017;
1:
AB012
(12 September 2017)
Translational Science
AB011. OS03.01. Expression of L-type amino acid transporter 1 is possible diagnostic and prognostic marker of thymic carcinoma
Mediastinum
2017;
1:
AB011
(12 September 2017)
Basic Science
AB010. OS02.04. Characterization of autoantibody in thymoma with myasthenia gravis by single-cell sequencing of B-cells
Mediastinum
2017;
1:
AB010
(12 September 2017)
Basic Science
AB009. OS02.03. Phase II trial of cetuximab and chemotherapy followed by surgical resection for locally advanced thymoma
Mediastinum
2017;
1:
AB009
(12 September 2017)
Basic Science
AB008. OS02.02. Identification of differentially expressed genes between thymoma and paraneoplastic thymic tissues
Mediastinum
2017;
1:
AB008
(12 September 2017)
Editorial
Robotic approach for mediastinal lesions: the surgery of extreme locations
Mediastinum
2017;
1:
8
(30 September 2017)
Basic Science
AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network
Mediastinum
2017;
1:
AB007
(12 September 2017)
Editorial
Thymic epithelial tumors: still enigmatic neoplasms!
Mediastinum
2017;
1:
7
(30 September 2017)
Clinical Science
AB006. OS01.06. Factors associated with survival in patients with thymoma: study of 523 cases from one institution
Mediastinum
2017;
1:
AB006
(12 September 2017)
Editorial
Setting the base for new therapeutic strategies against thymic epithelial tumors—miR-145-5p epigenetic regulation
Mediastinum
2017;
1:
6
(30 September 2017)
Clinical Science
AB005. OS01.05. Early prediction of response to target therapy by FDG-PET in thymic epithelial tumors: a monocentric experience
Mediastinum
2017;
1:
AB005
(12 September 2017)
Clinical Science
AB004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC
Mediastinum
2017;
1:
AB004
(12 September 2017)
Clinical Science
AB003. OS01.03. New proposed treatment for pure red cell aplasia thymoma-related
Mediastinum
2017;
1:
AB003
(12 September 2017)
Editorial
Relevance of PD-L1 expression status in thymic malignancies
Mediastinum
2017;
1:
3
(15 September 2017)
Clinical Science
AB002. OS01.02. A phase ii study of chemotherapy concurrent with radiotherapy in patients with unresectable advanced thymic tumors
Mediastinum
2017;
1:
AB002
(12 September 2017)
Clinical Science
AB001. OS01.01. Post op radiation may be detrimental in thymoma but not in thymic carcinoma tumors
Mediastinum
2017;
1:
AB001
(12 September 2017)
Disclosure:
The “Abstract Book for the 8th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2017)” was commissioned by the editorial office, Mediastinum without any sponsorship or funding.